PL4469459T3 - Sposób wytwarzania krystalicznego monohydratu chlorowodorku sitagliptyny - Google Patents

Sposób wytwarzania krystalicznego monohydratu chlorowodorku sitagliptyny

Info

Publication number
PL4469459T3
PL4469459T3 PL23702085.4T PL23702085T PL4469459T3 PL 4469459 T3 PL4469459 T3 PL 4469459T3 PL 23702085 T PL23702085 T PL 23702085T PL 4469459 T3 PL4469459 T3 PL 4469459T3
Authority
PL
Poland
Prior art keywords
hydrochloride monohydrate
preparing crystalline
crystalline sitagliptin
sitagliptin hydrochloride
preparing
Prior art date
Application number
PL23702085.4T
Other languages
English (en)
Inventor
Maciej Graużenis
Karol Sągol
Adam Hałuszczuk
Original Assignee
Zakłady Farmaceutyczne POLPHARMA S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zakłady Farmaceutyczne POLPHARMA S.A. filed Critical Zakłady Farmaceutyczne POLPHARMA S.A.
Publication of PL4469459T3 publication Critical patent/PL4469459T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL23702085.4T 2022-01-24 2023-01-24 Sposób wytwarzania krystalicznego monohydratu chlorowodorku sitagliptyny PL4469459T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22460007 2022-01-24
PCT/EP2023/051644 WO2023139276A1 (en) 2022-01-24 2023-01-24 Process for preparing crystalline sitagliptin hydrochloride monohydrate

Publications (1)

Publication Number Publication Date
PL4469459T3 true PL4469459T3 (pl) 2026-05-04

Family

ID=80448922

Family Applications (1)

Application Number Title Priority Date Filing Date
PL23702085.4T PL4469459T3 (pl) 2022-01-24 2023-01-24 Sposób wytwarzania krystalicznego monohydratu chlorowodorku sitagliptyny

Country Status (3)

Country Link
EP (1) EP4469459B1 (pl)
PL (1) PL4469459T3 (pl)
WO (1) WO2023139276A1 (pl)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US20080227786A1 (en) 2004-01-16 2008-09-18 Ferlita Russell R Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
RU2519717C2 (ru) 2008-07-03 2014-06-20 Рациофарм Гмбх Кристаллические соли ситаглиптина
WO2010012781A2 (en) 2008-07-29 2010-02-04 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
WO2011123641A1 (en) 2010-03-31 2011-10-06 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts
WO2012025944A2 (en) 2010-08-27 2012-03-01 Usv Limited Sitagliptin, salts and polymorphs thereof
US9108972B2 (en) 2011-03-03 2015-08-18 Cadila Healthcare Limited Salts of DPP-IV inhibitor
WO2015170340A2 (en) 2014-05-06 2015-11-12 Laurus Labs Private Limited Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
WO2016162877A1 (en) 2015-04-09 2016-10-13 Finochem Limited Harman "a process for preparing 7-[(3r)-3-amino-l-oxo-4-(2,4,5trifluorophenyl)butyi]- 5,6,7,8-tetrahydro-3-(trifluoromethyl)-l,2,4-triazolo[4,3-a]pyrazine hydrochloride monohydrate and its crystalline form"
CN110857302A (zh) * 2018-08-24 2020-03-03 江苏瑞科医药科技有限公司 一种西格列汀盐酸盐单水合物晶型的制备方法
WO2020109938A1 (en) 2018-11-27 2020-06-04 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof

Also Published As

Publication number Publication date
WO2023139276A1 (en) 2023-07-27
EP4469459A1 (en) 2024-12-04
EP4469459B1 (en) 2026-01-21

Similar Documents

Publication Publication Date Title
HUE070927T2 (hu) Eljárás izocianátok elõállítására
EP4355752A4 (en) PROCESS FOR THE PRODUCTION OF ORGANOTIN COMPOUNDS
PL4380932T3 (pl) Sposób wytwarzania aficamtenu
PT4208441T (pt) Processo para produção de isocianatos
IL314883A (en) Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
PL4377287T3 (pl) Sposób wytwarzania kwasu mlekowego
HUE068289T2 (hu) Eljárás heterociklidén-acetamid származékok elõállítására
IL304848A (en) The process of making risdiplam
HUE070539T2 (hu) Eljárás BTK-inhibitorok elõállítására
IL321171A (en) Crystalline forms of 2-oxoquinazoline
IL327495A (en) Process for manufacturing loxavir marboxil
ZA202212697B (en) Process for the preparation salts of triazole compounds
GB202319666D0 (en) Liquid-phase process for preparing oligonucleotides
IL290215A (en) A process for the preparation of crystalline form ii of sotagliflozin
PL4178969T3 (pl) Sposób uzyskiwania diosminy
GB202319631D0 (en) Liquid-phase process for preparing oligonuncleotides
EP3922621C0 (de) Prozess zur herstellung von propylen
IL319979A (en) ALOGABAT production process
EP3681880A4 (en) PROCESS FOR THE PREPARATION OF CRYSTALLINE TIPIRACIL HYDROCHLORIDE
IL318203A (en) Process for preparing modified benzamides
CA3307619A1 (en) Processes for preparing kras inhibitors
GB202317989D0 (en) Novel crystalline salt forms
IL320542A (en) High purity alkynyl amines for selective reduction
IL320938A (en) Process for preparing an oxacylopentane derivative
GB202010168D0 (en) Process for preparing remifentanil hydrochloride